Abstract

G protein-coupled receptors (GPCRs) exist within a landscape of interconvertible conformational states and in dynamic equilibrium between monomers and higher-order oligomers, both influenced by ligand binding. Here, we have shown that a homobivalent ligand formed by equal chromenopyrazole moieties as pharmacophores, connected by 14 methylene units, can modulate the dynamics of the cannabinoid CB2 receptor (CB2R) homodimerization by simultaneously binding both protomers of the CB2R-CB2R homodimer. Computational and pharmacological experimentals showed that one of the ligand pharmacophores binds to the orthosteric site of one protomer, and the other pharmacophore to a membrane-oriented pocket between transmembranes 1 and 7 of the partner protomer. This provides unique pharmacological properties, such as increased potency in Gi binding and increased recruitment of {beta}-arrestin. Thus, by modulating dimerization dynamics, it may be possible to fine-tune CB2R activity with potentially improved therapeutic outcomes. HIGHLIGHTSO_LIA homobivalent ligand of CB2R (PM369) modulates the dynamics of receptor homodimerization C_LIO_LIPM369 binds to the orthosteric site of one protomer and to a complementary, membrane-facing, site of the other protomer C_LIO_LIPM369 triggers CB2R homodimerization via the TM 1/7 interface that provides unique pharmacological properties C_LIO_LIPM369 potentiates signaling, increased potency in Gi binding and increased recruitment of {beta}-arrestin C_LIO_LIThese results highlight new approaches to control GPCR signaling C_LI GRAPHICAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=122 SRC="FIGDIR/small/593612v1_ufig1.gif" ALT="Figure 1"> View larger version (37K): org.highwire.dtl.DTLVardef@1736aeborg.highwire.dtl.DTLVardef@707654org.highwire.dtl.DTLVardef@168925borg.highwire.dtl.DTLVardef@60bc11_HPS_FORMAT_FIGEXP M_FIG C_FIG